{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/baxter-bax/",
 "dataUrl": "https://clearank.com/stock/baxter-bax/data.json",
 "title": "Baxter (BAX) Stock Forecast & Price Target (2026)",
 "description": "Baxter International (BAX) stock forecast 2026: buy, hold or sell? Pays a dividend. A US medical instruments & supplies stock on the NYSE.",
 "headline": "Baxter International Inc. (BAX)",
 "published": "2026-11-09T18:45:44+00:00",
 "modified": "2026-11-09T18:45:45.188+00:00",
 "generated": "2026-11-11T13:14:21.733Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by Roger Wohlner, Financial Journalist; prices delayed by up to a minute.",
 "asset": {
  "ticker": "BAX",
  "name": "Baxter International Inc.",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Medical Instruments & Supplies",
  "country": "United States",
  "website": "https://www.baxter.com"
 },
 "quote": {
  "price": 26.42,
  "previousClose": 26.41,
  "change": 0.01,
  "changePercent": 0.03786,
  "open": 26.18,
  "high": 26.49,
  "low": 25.57,
  "volume": 3830313,
  "averageVolume": 9462931,
  "marketCap": 13668339126,
  "fiftyTwoWeekHigh": 30,
  "fiftyTwoWeekLow": 15.73,
  "marketOpen": false,
  "asOf": "2026-11-10T23:51:19.000Z"
 },
 "statistics": {
  "pe": -21.83,
  "eps": -1.21,
  "dividendYield": 0.001514004542013626,
  "beta": 0.67,
  "priceToSales": 1.1767433,
  "priceToBook": 2.1013687,
  "revenueTtm": 11610999808,
  "grossMargin": 0.34864864864864864,
  "returnOnEquity": -0.09044
 },
 "technicals": {
  "rsi": 59.26,
  "macd": 0.4147,
  "sma50": 24.52,
  "sma200": 21.54,
  "rsiSignal": "Neutral",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Hold",
  "score": 57,
  "consensus": "Hold",
  "fairValue": null,
  "analystTarget": 26,
  "analystCount": 15,
  "wallStreetConsensus": "Hold",
  "generatedAt": "2026-11-10T23:51:19.000Z",
  "priceAtAnalysis": 26.42,
  "volatility": {
   "daily": 2.74,
   "risk": "standard"
  }
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 17.78,
    "base": 26.35,
    "upside90th": 39.05
   },
   {
    "year": 2028,
    "downside10th": 15.06,
    "base": 26.28,
    "upside90th": 45.84
   },
   {
    "year": 2029,
    "downside10th": 13.26,
    "base": 26.21,
    "upside90th": 51.8
   },
   {
    "year": 2030,
    "downside10th": 11.9,
    "base": 26.13,
    "upside90th": 57.41
   }
  ]
 },
 "faqCount": 7,
 "atAGlance": {
  "asOf": "November 10, 2026",
  "rating": "Hold",
  "score": 57,
  "evidence": [
   {
    "label": "Trend",
    "text": "Up: the price is above both its 50- and 200-day moving averages ($24.52 and $21.54)."
   }
  ]
 },
 "figures": {
  "asOf": "November 10, 2026",
  "earningsReaction": null,
  "insiders": null,
  "drawdown": {
   "years": 10,
   "worstFallPercent": -79.87,
   "peak": "February 2020",
   "trough": "March 2026",
   "recoveredBy": null,
   "recoveryMonths": null,
   "belowThatPeakNowPercent": -68.05,
   "fromHighNowPercent": -68.05,
   "oneYearHoldsPositivePercent": 42,
   "dividendsReinvested": true
  },
  "seasonality": {
   "years": 10,
   "bestMonth": {
    "month": "Jan",
    "averagePercent": 3,
    "upYearsPercent": 70
   },
   "worstMonth": {
    "month": "Oct",
    "averagePercent": -5.48,
    "upYearsPercent": 30
   }
  },
  "correlations": null,
  "analystTargets": {
   "analysts": 15,
   "low": 23,
   "median": 26,
   "high": 40,
   "mean": 27.25,
   "buy": 2,
   "hold": 12,
   "sell": 1
  },
  "dividend": {
   "yieldPercent": 0.1514,
   "annualPerShare": 0.04
  },
  "simulation": {
   "year": 2030,
   "base": 26.13,
   "percentile10": 11.9,
   "percentile90": 57.41,
   "note": "Monte Carlo simulation outcomes, not price targets"
  }
 },
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "ch-overview",
   "title": "BAX stock today, November 11, 2026: price, news and analyst targets",
   "text": [
    "As of November 10, 2026, Baxter International Inc. (BAX) trades at $26.42. Wall Street's median 12-month price target is $26.00 across 15 analysts, 1.6% below the price. CleaRank rates it Hold with a score of 57/100.",
    "Baxter International is trading near the top of its 52-week range after a steady climb, but the stock's recent gains sit against a weak earnings picture. The price of $26.42 is 1.6% below the analysts' median 12-month target of $26.00, and the consensus rating is Hold. The stock is above its 20-day, 50-day and 200-day averages, which is the strongest part of the chart. The open question for investors is whether the business can turn a 5.00% revenue gain into profit, since the trailing GAAP loss per share is -$1.21.",
    "The stock is up 47.68% over six months and 48.85% over the past year, and it trades 22.63% above its 200-day average. The 50-day average sits 13.80% above the 200-day average, which is the kind of spacing that shows a sustained rise rather than a single spike. The MACD line is positive and the 14-day RSI of 59.3 sits in the neutral zone, so momentum is supportive without signalling an overheated stock.",
    "The company reported a net profit margin of -5.3% and a return on equity of -9.04%, while the sector median return on equity is 7.3%. Its operating margin of 9.88% shows the core operations earn a profit before financing and other costs, but the net result is still a loss. The debt-to-equity ratio of 1.36 adds to the balance sheet pressure. CleaRank rates company health at 2 out of 5.",
    "At a price-to-sales ratio of 1.18, the stock is 65.3% below the sector median P/S of 3.4. That discount reflects the loss-making results rather than a bargain, because the price-to-earnings ratio is not meaningful with negative earnings. The stock's market value of $13.7B and its low beta of 0.67 against the S&P 500 place it as a less volatile holding than the market, with a typical daily move of 2.74%.",
    "Of 15 analysts, 2 rate the stock buy or strong buy, 12 rate it hold and 1 rates it sell. Three months ago, 2 of 13 ratings were buy. On October 30, 2026, JP Morgan kept its Neutral rating and Wells Fargo kept its Equal-Weight rating. On October 7, 2026, Barclays started coverage at Underweight. Citigroup kept its Neutral rating on October 5, 2026. The median target of $26.00 is 1.6% below the price, and the range runs from $23.00 to $40.00.",
    "CleaRank score 57/100 (Hold). 9 of 17 checks pass: trend 4 of 4, momentum 3 of 3, valuation and quality 2 of 3, analysts 0 of 3, track record 0 of 4.",
    "Baxter International Inc. is a global healthcare company focused on providing essential medical products and technologies used in hospitals, clinics, surgery centers, pharmacies, and home-care settings. Baxter International Inc. develops and supplies infusion systems, sterile intravenous solutions, injectable pharmaceuticals, parenteral nutrition therapies, advanced surgery products, patient monitoring and diagnostic technologies, smart beds, and respiratory care devices."
   ]
  },
  {
   "id": "ch-news",
   "title": "BAX stock news",
   "text": [
    "October 7, 2026·Barclays",
    "Barclays started coverage at Underweight on October 7, 2026, the most negative stance among the recent rating actions. It adds a voice of caution at a time when the stock has already risen sharply over the past year.",
    "October 30, 2026·JP Morgan",
    "JP Morgan kept its Neutral rating on October 30, 2026. The reiteration suggests the bank sees the shares as fairly valued rather than a clear buy or sell.",
    "October 30, 2026·Wells Fargo",
    "Wells Fargo kept its Equal-Weight rating on October 30, 2026, after keeping the same view on July 31, 2026. The unchanged stance over several months points to steady expectations for the stock.",
    "October 5, 2026·Citigroup",
    "Citigroup kept its Neutral rating on October 5, 2026. The rating matches the consensus Hold view and does not signal a change in the outlook."
   ],
   "lists": {
    "items": [
     "Barclays opens with an Underweight view October 7, 2026·Barclays Barclays started coverage at Underweight on October 7, 2026, the most negative stance among the recent rating actions. It adds a voice of caution at a time when the stock has already risen sharply over the past year.",
     "JP Morgan keeps Neutral stance October 30, 2026·JP Morgan JP Morgan kept its Neutral rating on October 30, 2026. The reiteration suggests the bank sees the shares as fairly valued rather than a clear buy or sell.",
     "Wells Fargo holds Equal-Weight October 30, 2026·Wells Fargo Wells Fargo kept its Equal-Weight rating on October 30, 2026, after keeping the same view on July 31, 2026. The unchanged stance over several months points to steady expectations for the stock.",
     "Citigroup maintains Neutral October 5, 2026·Citigroup Citigroup kept its Neutral rating on October 5, 2026. The rating matches the consensus Hold view and does not signal a change in the outlook."
    ]
   }
  },
  {
   "id": "ch-street",
   "title": "BAX price target 2026",
   "text": [
    "The base case is that BAX holds its position above its moving averages while the company works toward profitability, with the stock trading in a range that stays close to analyst expectations. Analysts expect earnings per share to shrink 7.4% this fiscal year to $2.10 and a further 2.7% next year to $2.05, while expecting revenue to grow 4.3% to $11.7B this year. That gap between sales growth and falling earnings is the main tension. The case would improve if revenue growth keeps pace with the 5.00% of the latest quarter and margins hold near the 9.88% operating margin, which could push the stock toward the $30.00 high. The case would weaken if the price falls back through the 20-day EMA at $25.22 and the 50-day SMA at $24.52, or if the lowest analyst target of $23.00 becomes the reference point. The highest target of $40.00 belongs to one of the more optimistic analysts and is far from the consensus."
   ],
   "tables": [
    {
     "caption": "Recent analyst rating actions on BAX",
     "columns": [
      "Date",
      "Firm",
      "Action",
      "Rating"
     ],
     "rows": [
      {
       "label": "Oct 30, 2026",
       "cells": [
        "JP Morgan",
        "Maintains",
        "Neutral"
       ]
      },
      {
       "label": "Oct 30, 2026",
       "cells": [
        "Wells Fargo",
        "Maintains",
        "Equal-Weight"
       ]
      },
      {
       "label": "Oct 7, 2026",
       "cells": [
        "Barclays",
        "Initiates",
        "Underweight"
       ]
      },
      {
       "label": "Oct 5, 2026",
       "cells": [
        "Citigroup",
        "Maintains",
        "Neutral"
       ]
      },
      {
       "label": "Jul 31, 2026",
       "cells": [
        "TD Cowen",
        "Maintains",
        "Hold"
       ]
      },
      {
       "label": "Jul 31, 2026",
       "cells": [
        "Wells Fargo",
        "Maintains",
        "Equal-Weight"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "ch-levels",
   "title": "BAX support and resistance levels",
   "text": [
    "Support sits first at the 20-day EMA of $25.22, the nearest level below the price and a short-term trend line that the stock has been trading above. Below it is the 50-day SMA at $24.52, which marks where the medium-term uptrend would be tested. The 200-day SMA at $21.54 is the longer-term trend line, and the 52-week low of $15.73 is the bottom of the range. Resistance is the 52-week high of $30.00, the nearest level above the price. A move above it would be a new high for the past year."
   ],
   "tables": [
    {
     "caption": "BAX support and resistance levels",
     "columns": [
      "Level",
      "What it is",
      "Price",
      "From the price"
     ],
     "rows": [
      {
       "label": "Resistance 1",
       "cells": [
        "52-week high",
        "$30.00",
        "+13.6%"
       ]
      },
      {
       "label": "Price",
       "cells": [
        "November 10, 2026",
        "$26.42",
        ""
       ]
      },
      {
       "label": "Support 1",
       "cells": [
        "20-day exponential average",
        "$25.22",
        "-4.5%"
       ]
      },
      {
       "label": "Support 2",
       "cells": [
        "50-day moving average",
        "$24.52",
        "-7.2%"
       ]
      },
      {
       "label": "Support 3",
       "cells": [
        "200-day moving average",
        "$21.54",
        "-18.5%"
       ]
      },
      {
       "label": "Support 4",
       "cells": [
        "52-week low",
        "$15.73",
        "-40.5%"
       ]
      }
     ]
    }
   ],
   "lists": {
    "items": [
     "RSI Neutral",
     "SMA cross Bullish",
     "Price vs SMA Bullish",
     "MACD Bullish"
    ]
   }
  },
  {
   "id": "ch-price",
   "title": "BAX stock price and trading"
  },
  {
   "id": "ch-fundamentals",
   "title": "BAX fundamentals and valuation",
   "text": [
    "Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, BAX trades at 1.18x, -65% versus the sector median of 3.40x.",
    "Return vs XLV: Since May 29, 2025, BAX has lost 14.0% against a gain of 42.3% for XLV.",
    "Revenue growth: Revenue grew 5.7% in FY2025 to $11.2B, from $10.6B a year earlier.",
    "Profit margin: The net margin was -8.5% in FY2025, down from -6.0% the year before.",
    "Loss-making: BAX lost $957M in FY2025."
   ]
  },
  {
   "id": "ch-history",
   "title": "BAX price history and drawdowns",
   "text": [
    "Against the market: BAX trailed the S&P 500 over this period: $7,033.44 against $40,115.",
    "A $10,000 investment in BAX in December 2016 would be worth about $7,033 today with dividends reinvested, compared with about $40,115 for the same investment in the S&P 500 benchmark (also with dividends reinvested)."
   ]
  },
  {
   "id": "ch-scenarios",
   "title": "BAX stock price prediction 2030",
   "text": [
    "CleaRank's simulation projects a price near $26.13 for BAX by 2030 in the base case, from $26.42 today (1.0x over 4 years). The 10th-percentile path ends near $11.90. These are outcomes of a Monte Carlo simulation run on BAX's historical return distribution, not price targets, and they assume no dividends are reinvested."
   ],
   "tables": [
    {
     "caption": "BAX simulated price paths by year",
     "columns": [
      "Year",
      "10th percentile",
      "Base case",
      "90th percentile",
      "range base today"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$17.78",
        "$26.35",
        "$39.05",
        ""
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$15.06",
        "$26.28",
        "$45.84",
        ""
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$13.26",
        "$26.21",
        "$51.80",
        ""
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$11.90",
        "$26.13",
        "$57.41",
        ""
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "ch-insiders",
   "title": "BAX insider trading",
   "text": [
    "Insider trading: No insider bought BAX shares on the open market in the last 18 months."
   ],
   "tables": [
    {
     "caption": "Insider transactions in BAX",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Jun 1, 2026",
       "cells": [
        "Anita A. Zielinski Chief Financial Officer",
        "Grant",
        "13.4K",
        "-"
       ]
      },
      {
       "label": "May 5, 2026",
       "cells": [
        "William A. Ampofo II Director",
        "Grant",
        "12.8K",
        "-"
       ]
      },
      {
       "label": "May 5, 2026",
       "cells": [
        "Jeffrey A Craig Director",
        "Grant",
        "12.8K",
        "-"
       ]
      },
      {
       "label": "May 5, 2026",
       "cells": [
        "Michael R McDonnell Director",
        "Grant",
        "12.8K",
        "-"
       ]
      },
      {
       "label": "May 5, 2026",
       "cells": [
        "Patricia B Morrison Director",
        "Grant",
        "12.8K",
        "-"
       ]
      },
      {
       "label": "May 5, 2026",
       "cells": [
        "Nancy M Schlichting Director",
        "Grant",
        "12.8K",
        "-"
       ]
      },
      {
       "label": "May 5, 2026",
       "cells": [
        "David Brent Shafer Chairman of the Board",
        "Grant",
        "12.8K",
        "-"
       ]
      },
      {
       "label": "May 5, 2026",
       "cells": [
        "Amy McBride Wendell Director",
        "Grant",
        "12.8K",
        "-"
       ]
      },
      {
       "label": "May 5, 2026",
       "cells": [
        "David S. Wilkes, M.D. Director",
        "Grant",
        "12.8K",
        "-"
       ]
      },
      {
       "label": "Feb 27, 2026",
       "cells": [
        "Cynthia Carlisle Officer",
        "Grant",
        "29.7K",
        "-"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "ch-faq",
   "title": "BAX stock forecast: questions people ask",
   "text": [
    "How these figures are computed, and where the data comes from: CleaRank methodology."
   ]
  },
  {
   "id": "ch-related",
   "title": "Compare BAX with similar assets",
   "links": [
    {
     "text": "ISRG Intuitive Surgical Inc. NASDAQ $450.04 -2.28%",
     "url": "https://clearank.com/stock/intuitive-surgical-isrg/"
    },
    {
     "text": "MDT Medtronic NYSE $101.59 -1.17%",
     "url": "https://clearank.com/stock/medtronic-mdt/"
    },
    {
     "text": "SYK Stryker Corp. NYSE $324.29 -0.44%",
     "url": "https://clearank.com/stock/stryker-syk/"
    },
    {
     "text": "IBRX ImmunityBio Inc. NASDAQ $6.75 -5.13%",
     "url": "https://clearank.com/stock/immunitybio-ibrx/"
    },
    {
     "text": "PFE Pfizer Inc. NYSE $29.23 -0.54%",
     "url": "https://clearank.com/stock/pfizer-pfe/"
    },
    {
     "text": "IONS Ionis Pharmaceuticals, Inc. NASDAQ $28.18 -9.11%",
     "url": "https://clearank.com/stock/ions-stock-analysis/"
    },
    {
     "text": "MOH Molina Healthcare Inc. NYSE $206.35 +1.48%",
     "url": "https://clearank.com/stock/moh-stock-analysis/"
    },
    {
     "text": "CRSP CRISPR Therapeutics AG NASDAQ $45.15 -9.77%",
     "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
    },
    {
     "text": "VTI vs SPY Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/vti-vs-spy/"
    },
    {
     "text": "XRP/USD vs ADA/USD Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/xrp-vs-ada/"
    },
    {
     "text": "CMG vs CAVA Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/cmg-vs-cava/"
    }
   ]
  }
 ],
 "faq": [
  {
   "question": "What is the BAX stock forecast?",
   "answer": "The analysts' median 12-month price target is $26.00, which is 1.6% below the current price of $26.42. The targets range from $23.00 to $40.00 across 15 analysts. The nearest level below the price is the 20-day EMA at $25.22, and the nearest level above it is the 52-week high of $30.00."
  },
  {
   "question": "What is the BAX price target?",
   "answer": "The median 12-month analyst target is $26.00, with the lowest target at $23.00 and the highest at $40.00. The consensus rating is Hold. The price of $26.42 sits just above the median target."
  },
  {
   "question": "Is BAX a buy or sell today?",
   "answer": "Of 15 analysts, 2 rate the stock buy or strong buy, 12 rate it hold and 1 rates it sell, so the consensus rating is Hold. CleaRank rates the stock Hold with a score of 57 out of 100. The stock is 22.63% above its 200-day average and 7.76% above its 50-day average, and the trend is up."
  },
  {
   "question": "How has BAX performed over the past year?",
   "answer": "The stock rose 48.85% over the past year and 47.68% over six months. Over the past three months it fell 4.31%, so the gains came mostly in the earlier part of the year."
  },
  {
   "question": "Is Baxter profitable?",
   "answer": "No. The GAAP earnings per share over the last 12 months is -$1.21, and the net profit margin is -5.3%. The operating margin of 9.88% is positive, so the losses come from costs below the operating line."
  },
  {
   "question": "Does BAX pay a dividend?",
   "answer": "The annual dividend is $0.04 per share, which gives a trailing dividend yield of 0.15%. The yield is small compared with the stock's price."
  },
  {
   "question": "How risky is BAX compared with the market?",
   "answer": "The stock has a beta of 0.67 against the S&P 500, so it has moved less than the broad market. Its typical daily move, based on 30-day standard deviation, is 2.74%."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "ISRG",
    "name": "Intuitive Surgical Inc. NASDAQ",
    "price": "$450.04",
    "change": "-2.28%",
    "url": "https://clearank.com/stock/intuitive-surgical-isrg/"
   },
   {
    "ticker": "MDT",
    "name": "Medtronic NYSE",
    "price": "$101.59",
    "change": "-1.17%",
    "url": "https://clearank.com/stock/medtronic-mdt/"
   },
   {
    "ticker": "SYK",
    "name": "Stryker Corp. NYSE",
    "price": "$324.29",
    "change": "-0.44%",
    "url": "https://clearank.com/stock/stryker-syk/"
   },
   {
    "ticker": "IBRX",
    "name": "ImmunityBio Inc. NASDAQ",
    "price": "$6.75",
    "change": "-5.13%",
    "url": "https://clearank.com/stock/immunitybio-ibrx/"
   },
   {
    "ticker": "PFE",
    "name": "Pfizer Inc. NYSE",
    "price": "$29.23",
    "change": "-0.54%",
    "url": "https://clearank.com/stock/pfizer-pfe/"
   },
   {
    "ticker": "IONS",
    "name": "Ionis Pharmaceuticals, Inc. NASDAQ",
    "price": "$28.18",
    "change": "-9.11%",
    "url": "https://clearank.com/stock/ions-stock-analysis/"
   },
   {
    "ticker": "MOH",
    "name": "Molina Healthcare Inc. NYSE",
    "price": "$206.35",
    "change": "+1.48%",
    "url": "https://clearank.com/stock/moh-stock-analysis/"
   },
   {
    "ticker": "CRSP",
    "name": "CRISPR Therapeutics AG NASDAQ",
    "price": "$45.15",
    "change": "-9.77%",
    "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
   }
  ],
  "comparisons": [
   {
    "ticker": "VTI vs SPY Comparison",
    "name": "",
    "url": "https://clearank.com/compare/vti-vs-spy/"
   },
   {
    "ticker": "XRP/USD vs ADA/USD Comparison",
    "name": "",
    "url": "https://clearank.com/compare/xrp-vs-ada/"
   },
   {
    "ticker": "CMG vs CAVA Comparison",
    "name": "",
    "url": "https://clearank.com/compare/cmg-vs-cava/"
   }
  ],
  "Newly Tracked": [
   {
    "ticker": "TEVA",
    "text": "Teva Pharmaceutical Industries Ltd.",
    "url": "https://clearank.com/stock/teva-pharmaceutical-teva/"
   },
   {
    "ticker": "CAH",
    "text": "Cardinal Health, Inc.",
    "url": "https://clearank.com/stock/cardinal-health-cah/"
   },
   {
    "ticker": "NVAX",
    "text": "Novavax Inc.",
    "url": "https://clearank.com/stock/novavax-nvax/"
   },
   {
    "ticker": "HL",
    "text": "Hecla Mining Company",
    "url": "https://clearank.com/stock/hecla-mining-hl/"
   },
   {
    "ticker": "CTVA",
    "text": "Corteva Inc.",
    "url": "https://clearank.com/stock/corteva-ctva/"
   }
  ],
  "Top Movers (latest session)": [
   {
    "ticker": "MRDN",
    "text": "↓ 23.90%",
    "url": "https://clearank.com/stock/mrdn-stock-analysis/"
   },
   {
    "ticker": "HIMS",
    "text": "↓ 16.61%",
    "url": "https://clearank.com/stock/hims-hers-health-hims/"
   },
   {
    "ticker": "MOD",
    "text": "↑ 9.87%",
    "url": "https://clearank.com/stock/mod-stock-analysis/"
   },
   {
    "ticker": "OFIX",
    "text": "↓ 9.87%",
    "url": "https://clearank.com/stock/ofix-stock-analysis/"
   },
   {
    "ticker": "WDC",
    "text": "↑ 9.86%",
    "url": "https://clearank.com/stock/western-digital-wdc/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "AZN",
    "text": "AstraZeneca",
    "url": "https://clearank.com/stock/astrazeneca-azn/"
   },
   {
    "ticker": "BDX",
    "text": "Becton, Dickinson and Company",
    "url": "https://clearank.com/stock/bdx-stock-analysis/"
   },
   {
    "ticker": "ISRG",
    "text": "Intuitive Surgical",
    "url": "https://clearank.com/stock/intuitive-surgical-isrg/"
   },
   {
    "ticker": "RMD",
    "text": "ResMed",
    "url": "https://clearank.com/stock/rmd-stock-analysis/"
   },
   {
    "ticker": "WST",
    "text": "West Pharmaceutical",
    "url": "https://clearank.com/stock/wst-stock-analysis/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": [
      "CleaRank Financial AI",
      "CleaRank (Clear Rank)"
     ],
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free, and so is the Free plan of its trading workbench; CleaRank is paid for by yearly Pro and Unlimited subscriptions to that workbench, which combines a trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. It uses no affiliate links and takes no payment from the brokers, prop firms or companies it rates or writes about.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@type": "Place",
      "@id": "https://clearank.com/#place",
      "address": {
       "@type": "PostalAddress",
       "streetAddress": "Beni Berman 2",
       "addressLocality": "Netanya",
       "addressRegion": "Center",
       "postalCode": "4249330",
       "addressCountry": "IL"
      }
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@type": "SoftwareApplication",
      "@id": "https://clearank.com/#app",
      "name": "CleaRank",
      "url": "https://clearank.com/"
     },
     "founder": {
      "@type": "Person",
      "@id": "https://clearank.com/writer/shaundavidb/#person",
      "name": "Shaun David",
      "url": "https://clearank.com/writer/shaundavidb/"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/og/mi/stock/baxter-bax.png",
     "url": "https://clearank.com/og/mi/stock/baxter-bax.png",
     "width": "1200",
     "height": "630",
     "caption": "Baxter International Inc. (BAX) analysis by CleaRank",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/baxter-bax/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": 1,
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": 2,
       "item": {
        "@id": "https://clearank.com/stock/",
        "name": "Stocks"
       }
      },
      {
       "@type": "ListItem",
       "position": 3,
       "item": {
        "@id": "https://clearank.com/stock/baxter-bax/",
        "name": "Baxter International Inc. (BAX)"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/baxter-bax/#webpage",
     "url": "https://clearank.com/stock/baxter-bax/",
     "name": "Baxter (BAX) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-11-09T18:45:44+00:00",
     "dateModified": "2026-11-09T18:45:45+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/og/mi/stock/baxter-bax.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/baxter-bax/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/roger-wohlner/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/roger-wohlner/#person",
     "name": "Roger Wohlner",
     "jobTitle": "Financial Journalist",
     "url": "https://clearank.com/writer/roger-wohlner/",
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/baxter-bax/#richSnippet",
     "headline": "Baxter (BAX) Stock Forecast & Price Target (2026)",
     "name": "Baxter (BAX) Stock Forecast & Price Target (2026)",
     "description": "Baxter International (BAX) stock forecast 2026: buy, hold or sell? Pays a dividend. A US medical instruments & supplies stock on the NYSE.",
     "datePublished": "2026-11-09T18:45:44+00:00",
     "dateModified": "2026-11-09T18:45:45+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/market-insights/methodology/",
     "about": {
      "@type": "Corporation",
      "name": "Baxter International Inc.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "BAX"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NYSE"
       }
      ],
      "description": "Baxter International Inc. is a global healthcare company focused on providing essential medical products and technologies used in hospitals, clinics, surgery centers, pharmacies, and home-care settings. Baxter International Inc.",
      "tickerSymbol": "BAX",
      "sameAs": "https://www.baxter.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/baxter-bax/#webpage"
     },
     "image": {
      "@type": "ImageObject",
      "url": "https://clearank.com/og/mi/stock/baxter-bax.png",
      "width": 1200,
      "height": 630
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/baxter-bax/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is the BAX stock forecast?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The analysts' median 12-month price target is $26.00, which is 1.6% below the current price of $26.42. The targets range from $23.00 to $40.00 across 15 analysts. The nearest level below the price is the 20-day EMA at $25.22, and the nearest level above it is the 52-week high of $30.00."
     }
    },
    {
     "@type": "Question",
     "name": "What is the BAX price target?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The median 12-month analyst target is $26.00, with the lowest target at $23.00 and the highest at $40.00. The consensus rating is Hold. The price of $26.42 sits just above the median target."
     }
    },
    {
     "@type": "Question",
     "name": "Is BAX a buy or sell today?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Of 15 analysts, 2 rate the stock buy or strong buy, 12 rate it hold and 1 rates it sell, so the consensus rating is Hold. CleaRank rates the stock Hold with a score of 57 out of 100. The stock is 22.63% above its 200-day average and 7.76% above its 50-day average, and the trend is up."
     }
    },
    {
     "@type": "Question",
     "name": "How has BAX performed over the past year?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The stock rose 48.85% over the past year and 47.68% over six months. Over the past three months it fell 4.31%, so the gains came mostly in the earlier part of the year."
     }
    },
    {
     "@type": "Question",
     "name": "Is Baxter profitable?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "No. The GAAP earnings per share over the last 12 months is -$1.21, and the net profit margin is -5.3%. The operating margin of 9.88% is positive, so the losses come from costs below the operating line."
     }
    },
    {
     "@type": "Question",
     "name": "Does BAX pay a dividend?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The annual dividend is $0.04 per share, which gives a trailing dividend yield of 0.15%. The yield is small compared with the stock's price."
     }
    },
    {
     "@type": "Question",
     "name": "How risky is BAX compared with the market?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The stock has a beta of 0.67 against the S&P 500, so it has moved less than the broad market. Its typical daily move, based on 30-day standard deviation, is 2.74%."
     }
    }
   ]
  }
 ]
}